Among 1,200+ telehealth users who lost over 20% of body weight, 52% had behavioral or psychological support. High prices drove most platform switching.
Recap by typeshit. Full story at Yahoo Finance.
A short post credits scientists with finding axolotl peptides that kill breast cancer cells. It names no study or team, so treat it as an early claim.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
CEO J. David Warren, who did early research on elamipretide, says the company will target metabolic health and muscle preservation. It's also weighing GLP-1 companion products.
Loading…